Join to View Full Profile
250 E Broad StSuite 250Columbus, OH 43215
Phone+1 614-864-4919
Dr. Portman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University/Mt Carmel HospitalResidency, Obstetrics and Gynecology, 1990 - 1994- Ohio State University College of MedicineClass of 1990
Certifications & Licensure
OH State Medical License 1991 - 2026
Publications & Presentations
PubMed
- ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-,-mutated, metastatic breast cancer.Matthew P Goetz, Seth A Wander, Thomas Bachelot, Alexandre de Nonneville, Einav Nili Gal-Yam
Future Oncology. 2025-04-13 - 1 citationsEffects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.Shari B Goldfarb, Sarah L Sammons, Jane L Meisel, Timothy J Pluard, Simon N Jenkins
Clinical Breast Cancer. 2025-04-01 - 1 citationsOral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials.Risa Kagan, James A Simon, Steven R Goldstein, Barry S Komm, Simon N Jenkins
Menopause. 2024-06-01
Press Mentions
Therapy Areas: CardiovascularMarch 25th, 2025- Sermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on Urogenital Symptoms in Patients with ESR1-Mutated ER+/HER2- Metastatic Breast CancerJanuary 29th, 2025
- Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer SettingAugust 27th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
